申请人:[en]GASHERBRUM BIO , INC.
公开号:WO2023138684A1
公开(公告)日:2023-07-27
It relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
它一般涉及 GLP-1 激动剂和包含 GLP-1 激动剂的药物组合物,以及治疗与 GLP-1 相关的疾病、紊乱或病症的方法。